Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 5/20 | 0.65 |
| ▸ | HTT | P42858 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6048148 | 0.86 | CYP19A1 (0.65) | HTR6HTTSMN1; SMN2LMNAPKM | |
| SCHEMBL28864522 | 0.86 | LMNA (0.68) | HTTSMN1; SMN2LMNAPKMMAPK1 | |
| SCHEMBL2215125 | 0.85 | CA1 (0.62) | HTTSMN1; SMN2LMNAPKMMAPK1 | |
| SCHEMBL19581689 | 0.85 | CYP19A1 (0.68) | HTR6HTTLMNAKMT2ACA1 | |
| SCHEMBL17724590 | 0.85 | CYP19A1 (0.68) | HTR6HTTLMNAKMT2ACA1 | |
| SCHEMBL5280989 | 0.85 | LMNA (0.55) | HTR6HTTSMN1; SMN2LMNAPKM | |
| SCHEMBL6073370 | 0.84 | CA12 (0.59) | HTR6HTTSMN1; SMN2LMNAPKM | |
| Hydrochloric Acid SCHEMBL6339594 | 0.84 | CA1 (0.61) | HTTSMN1; SMN2LMNAPKMMAPK1 | |
| SCHEMBL6341219 | 0.83 | LMNA (0.79) | HTTSMN1; SMN2LMNAPKMMAPK1 | |
| SCHEMBL23109150 | 0.82 | HTT (0.60) | HTR6HTTSMN1; SMN2LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050187246-A1 | Cell proliferation inhibitors | LI QUN (US) | 2005-08-25 | — | — | US | claimed |
| US-20030096856-A1 | Cell proliferation inhibitors | ABBVIE INC. | 2003-05-22 | — | — | US | claimed |
| EP-1181269-A1 | CELL PROLIFERATION INHIBITORS | ABBOTT LABORATORIES (US) | 2002-02-27 | — | — | EP | claimed |
| WO-2000073264-A1 | CELL PROLIFERATION INHIBITORS | ABBOTT LABORATORIES (US) | 2000-12-07 | — | — | WO | claimed |
| US-20050187246-A1 | Cell proliferation inhibitors | LI QUN (US) | 2005-08-25 | — | — | US | disclosed |
| US-6924304-B2 | Cell proliferation inhibitors | ABBOTT LABORATORIES (US) | 2005-08-02 | — | — | US | disclosed |
| US-20030096856-A1 | Cell proliferation inhibitors | ABBVIE INC. | 2003-05-22 | — | — | US | disclosed |
| US-6521658-B1 | Cell proliferation inhibitors | ABBOTT LABORATORIES | 2003-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096856-A1 | Cell proliferation inhibitors | MKI67, CCNI, CCNA1 | HTR6 2930/4885HTT 4313/4885SMN1; SMN2 1869/4885 |
| US-20050187246-A1 | Cell proliferation inhibitors | MKI67, CCNI, CCNC | HTR6 2563/4885HTT 4031/4885SMN1; SMN2 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.